pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ultomiris
drug · antibody
save

ravulizumab LA

Marketedupdated 6mo ago
by Alexion Pharmaceuticals Inc🔗 ChEMBL
Approved
annual revenue · 2024–2024peak $3.9B
2024: $3.9B2024$3.9B
community read0 votes

🐶 often sniffed alongside

top 1
  • tagApproval72 co-mentions · 18 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for hemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria and 11 investigational indications.

targets

Complement C5

all catalysts(0)

nothing on the calendar yet

Trials studying ravulizumab LA

  • phase3Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)recruitingn=20
  • —Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorderrecruitingn=35
  • —Real-life Treatment Outcomes of Ravulizumab in PNHactive not recruitingn=64
  • —Ravulizumab Outcomes in Polish Patients With aHUSrecruitingn=80
  • phase3Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)recruitingn=19
  • phase3ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKEcompletedn=544
  • phase3Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantationrecruitingn=450
  • —Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravisrecruitingn=50

News(6)

  • A hepatitis B hold lifted and drug tabled; Ultomiris' accelerated approval
    Plus news about Biohaven, Arcus Biosciences and a Boehringer Ingelheim and Microsoft collaboration. Hold on Arbutus drug lifted: It’s been a long, tough road for Arbutus Biopharma. The company has
    endpoints · 25d ago
  • AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
    AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
    biospace · 3mo ago
  • AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
    AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
    biospace · 3mo ago
  • FDA scientists question Capricor data; Legend CEO steps down
    Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
    biopharma_dive · 3mo ago
  • AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
    AstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…
    biospace · 3mo ago
  • Updated: AstraZeneca foresees blockbuster sales for Claudin 18.2 ADC, but Ultomiris flops in rare disease
    AstraZeneca said Monday that a key late-stage trial of its Claudin 18.2-targeting ADC in stomach cancer had succeeded, albeit with a caveat — but another Phase 3 trial of Ultomiris yielded subpar r…
    endpoints · 3mo ago
brand
Ultomiris
trade names
Ultomiris
generic
ravulizumab
MOA
Complement C5 inhibitor
indication
Delayed Graft Function (DGF)
phase
marketed
approved
2018-12-21
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?